AllSci News
BrightGene posts early data for oral dual GLP-1/GIP agonist in obesity
BrightGene Bio-Medical Technology (SSE: 688166), based in Suzhou, China, reported topline Phase I results for BGM0504, an oral GLP-1/GIP dual receptor agonist,…
Ocugen plans Phase III for gene therapy after positive data in geographic atrophy
Ocugen (NASDAQ: OCGN), a Pennsylvania-based biotechnology company, reported 12-month topline data from its Phase II ArMaDa trial showing that OCU410, a one-time…
Innovent’s efdamrofusp alfa meets Phase III endpoint in nAMD
Innovent Biologics (HKEX: 01801), the Suzhou- and San Francisco-based biopharmaceutical company, reported that its dual-target fusion protein efdamrofusp alfa (IBI302) met the…
Kelun-Bio moving TAA-PD-L1 bispecific ADC into clinic in China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that its Investigational New Drug application for SKB103, a tumor associated antigen (TAA)/PD-L1 bispecific antibody-drug…
Gilead moves on Ouro’s BCMA TCE for up to USD 2.2b with Galapagos in line to support
Gilead Sciences announced a definitive agreement to acquire San Francisco-based Ouro Medicines in a deal worth up to USD 2.175 billion. The…
Calidi to advance IL-15-armed onco virus into first-in-human in Australia
Calidi Biotherapeutics, based in San Diego, has engaged Avance Clinical, a full-service contract research organization (CRO), to facilitate Australian regulatory approval and…
Amani raises USD 25m Series A, in-licenses AZ compound for clozapine FDC
Amani Therapeutics, a newly formed biotechnology company based in New York, has closed a USD 25 million Series A financing round to…
BMS picks two AI-discovered ALS targets from insitro collaboration
insitro and Bristol Myers Squibb expanded their option-based discovery collaboration in amyotrophic lateral sclerosis (ALS), with Bristol Myers Squibb (BMS) nominating two…
Aspen makes late breaking presentation of sasineprocel’s improvements in early trial for Parkinson’s
Aspen Neuroscience reported 12-month data from the ASPIRO clinical trial evaluating sasineprocel (ANPD001), an autologous iPSC-derived dopaminergic neuron precursor cell therapy, in…
Pfizer and Valneva aim to file Lyme disease vaccine despite statistical fail in Phase III
Pfizer (NYSE: PFE) and Valneva (Nasdaq: VALN) reported Phase III results for their Lyme disease vaccine candidate PF-07307405 (LB6V, formerly VLA15), showing…
Verily secures USD 300m to scale AI health platform, signaling strategic shift from Alphabet
Verily Health Inc., a precision health technology company headquartered in Dallas, TX, has closed a USD 300 million investment round to fund…
Pfizer calls halt to Phase I development of Seagen-acquired CD228 ADC
Pfizer has terminated its Phase I PF-08046031 clinical trial in adults with advanced melanoma and other solid tumors, according to an update…
Novo Nordisk adds high-dose Wegovy option in the US
The US FDA has approved Wegovy HD (semaglutide) 7.2 mg for weight loss and long-term weight maintenance in certain adults with obesity,…
ImmunoBrain posts early safety data for PD-L1 against Alzheimer’s
ImmunoBrain, a New York–based clinical-stage company, presented Phase Ib data for IBC-Ab002, an anti-PD-L1 monoclonal antibody in early Alzheimer’s disease, at the…
Triana’s brain-penetrant molecular glue degrader TRI-611 enters clinic set for ALK+ NSCLC
Triana Biomedicines, a privately held biotechnology company based in Lexington, Massachusetts, has dosed the first patient in a Phase I/II clinical trial…
The AllSci Brief
Systematic R&D and deal news. Daily.